image

32.3.4. Guidelines for sFLC assessment in WM

Chapter 32

32.3.4. Guidelines for sFLC assessment in WM

The utility of sFLC assessment in WM is discussed in a number of guidelines for diagnosis or monitoring of WM[703][710][1125]. They recommend that sFLC levels are not routinely measured in all patients, but are useful in certain situations. For example, ESMO guidelines[1125] state that measurement of sFLCs is clinically indicated when there is suspicion of AL amyloidosis or renal failure, and in the rare event of a patient with measurable sFLCs but non-quantifiable IgM levels.

An update of the consensus panel criteria for the assessment of clinical response in patients with WM stated that whilst there were insufficient data to incorporate sFLC assessments into the revised criteria, further prospective evaluation was encouraged[703]. Similarly, British guidelines also highlight the potential utility of sFLC measurements for the assessment of response in WM[710] .